![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercebiotech.com/biotech/aslans-dream-challenging-dupixent-dies-cash-strapped-biotech-winds-down
https://www.globenewswire.com/news-release/2024/07/17/2914447/0/en/ASLAN-Pharmaceuticals-Announces-it-Has-Filed-for-Voluntary-Liquidation-of-Its-Sole-Operating-Subsidiary-and-is-Commencing-Steps-to-Place-Itself-Into-Voluntary-Liquidation.html
https://www.globenewswire.com/news-release/2024/07/15/2912960/0/en/ASLAN-Pharmaceuticals-Announces-Receipt-of-Nasdaq-Delisting-Determination-Has-Determined-Not-to-Appeal.html
https://www.globenewswire.com/news-release/2024/06/14/2899196/0/en/ASLAN-Pharmaceuticals-Announces-Plan-to-Implement-ADS-Ratio-Change.html
https://www.globenewswire.com/news-release/2024/05/21/2885431/0/en/ASLAN-Pharmaceuticals-Presents-Late-Breaking-Translational-Data-on-Eblasakimab-in-COPD-at-the-American-Thoracic-Society-International-Conference.html
https://www.globenewswire.com/news-release/2024/05/09/2878618/0/en/ASLAN-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2024/05/07/2876615/0/en/ASLAN-Pharmaceuticals-to-Present-Additional-Data-From-Interim-Analysis-of-TREK-DX-Phase-2-Study-of-Eblasakimab-in-Dupilumab-Experienced-Atopic-Dermatitis-Patients-During-Virtual-KO.html
https://www.globenewswire.com/news-release/2024/05/02/2874243/0/en/ASLAN-Pharmaceuticals-Announces-Expansion-of-its-Collaboration-With-Zenyaku-to-Investigate-the-Biology-Underlying-Differential-Effects-of-Eblasakimab-Compared-to-Other-Biologics.html
https://www.globenewswire.com/news-release/2024/04/30/2872039/0/en/ASLAN-Pharmaceuticals-to-Host-KOL-Panel-Discussion-on-Treatment-Options-for-Atopic-Dermatitis-Patients-With-an-Inadequate-Response-to-Dupilumab.html
https://www.globenewswire.com/news-release/2024/04/24/2868471/0/en/ASLAN-Pharmaceuticals-Announces-Late-Breaking-Abstract-on-Eblasakimab-in-COPD-Accepted-for-Presentation-at-the-American-Thoracic-Society-International-Conference.html